Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV)

× No keyword cloud information.

15 in total

1. In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.

Authors: B M Sadler; C Gillotin; Y Lou; D S Stein
Journal: Antimicrob Agents Chemother Date: 2001-03 Impact factor: 5.191

2. Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz.

Authors: Rosario Calvo; John C Lukas; Monica Rodriguez; M Angeles Carlos; Elena Suarez
Journal: Br J Clin Pharmacol Date: 2002-02 Impact factor: 4.335

3. Protein binding of clindamycin in sera of patients with AIDS.

Authors: J F Flaherty; G Gatti; J White; J Bubp; M Borin; J G Gambertoglio
Journal: Antimicrob Agents Chemother Date: 1996-05 Impact factor: 5.191

4. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.

Authors: J A Bilello; P A Bilello; K Stellrecht; J Leonard; D W Norbeck; D J Kempf; T Robins; G L Drusano
Journal: Antimicrob Agents Chemother Date: 1996-06 Impact factor: 5.191

5. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.

Authors: A Barrail-Tran; F Mentré; C Cosson; C Piketty; C Chazallon; L Gérard; P M Girard; A M Taburet
Journal: Antimicrob Agents Chemother Date: 2009-12-07 Impact factor: 5.191

6. In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Authors: Steffen Wildum; Daniela Paulsen; Kai Thede; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal: Antimicrob Agents Chemother Date: 2013-08-19 Impact factor: 5.191

7. Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma.

Authors: Sreeja Sudhakaran; Craig R Rayner; Jian Li; David C M Kong; Neil M Gude; Roger L Nation
Journal: Br J Clin Pharmacol Date: 2006-09-19 Impact factor: 4.335

8. The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Authors: Marta Boffito; Patrick G Hoggard; Helen E Reynolds; Stefano Bonora; E Rhiannon Meaden; Alessandro Sinicco; Giovanni Di Perri; David J Back
Journal: Br J Clin Pharmacol Date: 2002-09 Impact factor: 4.335

9. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

Authors: Hilde Azijn; Ilse Tirry; Johan Vingerhoets; Marie-Pierre de Béthune; Guenter Kraus; Katia Boven; Dirk Jochmans; Elke Van Craenenbroeck; Gaston Picchio; Laurence T Rimsky
Journal: Antimicrob Agents Chemother Date: 2009-11-23 Impact factor: 5.191

10. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.

Authors: José Moltó; Manuel José Barbanoj; Cristina Miranda; Asunción Blanco; José Ramón Santos; Eugenia Negredo; Joan Costa; Pere Domingo; Bonaventura Clotet; Marta Valle
Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447